Abstract
Vaccine hesitancy is a major threat to public health. While the root causes of vaccine hesitancy are numerous, they largely revolve around some form of perceived risk to the self. In particular, the unknown long-term risks are amongst the most frequently cited concerns. In this work, we show that regardless of their peak onset following vaccination, the incidence of adverse outcomes will follow some distribution f (x| µ, σ2) of mean onset µ, and standard deviation σ, and variance σ2. Despite the small proportion of events at the tails of these distributions, the large-scale public deployment of vaccines would imply that any signal for a given adverse outcome would be observed soon after distribution begins, even in cases where tx < tµ−3σ. The absence of such an early signal, however low, would suggest that long term effects are unlikely and that vaccine safety is therefore likely. Indeed, when enough individuals have been exposed to a new therapy - even if the majority of adverse outcomes only manifest at a future time tµ, the number of adverse outcomes given by the cumulative density function (CDF) near t0 + dt > 0. Otherwise stated:
We evoke the theory behind normal (Gaussian) and skew-normal distributions and use Chebyshev’s Theorem to evaluate the COVID-19 vaccine data as an example. The findings of this study are not vaccine-specific and can be applied to assess the health effects of the mass distribution of any good, treatment or policy at large.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data was utilized in this study
